Download Free Cardiotoxicity Of Chemotherapeutic Agents Book in PDF and EPUB Free Download. You can read online Cardiotoxicity Of Chemotherapeutic Agents and write the review.

Cardiotoxicity may be caused by radiotherapy and/or anticancer agents for many malignancies, adverse effects of some drugs in the context of medical intervention or heavy metal intake, especially during the anticancer therapy. This book intends to bring forward the recent development in toxicities from cancer treatment. It updates the possible mechanisms of cardiotoxicities of some anticancer agents and the suggested prevention and treatment strategies. This book contains many valuable contributions from the researchers in oncology and cardiology as well as the clinicians who are experts in this field.
This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality. This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity. - Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients - Written by world-leading experts in the field of cardiotoxicity - Includes high-quality images, case studies, and test questions - Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. - Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology - Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity - Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications
The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.
The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease.
The Chemotherapy Source Book, Fourth Edition pulls together all the current information on the chemotherapeutic management of cancer patients, including choice of chemotherapeutic agents, use of combinations, and toxicity of individual drugs. Organized by disease site, the book brings together pharmacologic and patient management information in one source that clinicians can consult for any question encountered in the delivery of chemotherapy. This updated Fourth Edition includes new drugs as well as new indications for older drugs. Content has been streamlined to provide essential information more quickly for the busy practitioner. Plus, this edition is softcover for greater portability and convenience.
This open access book presents a comprehensive overview of dilated cardiomyopathy, providing readers with practical guidelines for its clinical management. The first part of the book analyzes in detail the disease’s pathophysiology, its diagnostic work up as well as the prognostic stratification, and illustrates the role of genetics and gene-environment interaction. The second part presents current and future treatment options, highlighting the importance of long-term and individualized treatments and follow-up. Furthermore, it discusses open issues, such as the apparent healing phenomenon, the early prognosis of arrhythmic events or the use of genetic testing in clinical practice. Offering a multidisciplinary approach for optimizing the clinical management of DCM, this book is an invaluable aid not only for the clinical cardiologists, but for all physicians involved in the care of this challenging disease.
Imaging technologies are the cornerstone in the diagnosis and staging of benign and malignant lesions in the liver and pancreas. Although the methods are partly competing, they often need to be used in a complementary way in order to obtain optimal results for decision making. The introduction of new and refined non-invasive imaging technologies has lately led to a major progress in the diagnostic approach to diseases of the digestive system. For example, this is the case with echo-enhanced sonography: This technique is based on the property of microbubbles to resonate and emit harmonic waves in an ultrasound field. The initial method, defined as 'second harmonic imaging', was limited by the incapacity to separate the signals obtained from the bubbles and the tissue texture. This procedure has been replaced by the pulse inversion imaging technique which now gives a much better picture quality, allowing to depict the vascularization pattern of distinct lesions in the liver and pancreas. Similarly, the performance of other key imaging modalities such as CT-scan, magnetic resonance imaging, Doppler sonography and endosonography has been improved. Clinicians seeking current information on modern imaging modalities for diagnosis, differentiation and staging of gastrointestinal diseases will find this publication very useful.
The Department of Cardiology at The University of Texas MD Anderson Cancer Center was established on September, 1, 2000. In the past 15 years, we have evaluated and treated more than 10,000 cancer patients with cancer ther¬apy-related cardiovascular complications. Three years ago, we initiated the MD Anderson Practice (MAP) project to distillate our practice patterns into al¬gorithms to be shared with the onco-cardiology community. Because cancer is often an exclusion criterion for cardiology studies, purely evidence-based man¬agement of cancer therapy-related cardiovascular complications is not possible. With this vacuum of knowledge, various "guidelines" have proliferated that are either misleading or difficult to practice. In this manual, we present 16 MAPs that have been extensively reviewed by the cardiologists at MD Anderson. These MAPs should be considered our best practices rather than "guidelines." These MAPs will be updated frequently to reflect advances in the field. This manual con¬sists of MAPs, figures, and tables. We hope you will find these materials useful to your practice and provide us with feedback to improve these MAPs.